← Back to Search

Platinum-based Chemotherapy

Aroplatin for Advanced Colorectal Cancer

Phase 2

Waitlist Available

Research Sponsored by Aronex Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Women of child-bearing potential must have a negative urine or serum pregnancy test

Colorectal cancer, locally recurrent, unresectable or metastatic disease (AJCC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see how well it works and how long it works for patients with advanced colorectal cancer.

Who is the study for?

This trial is for adults with advanced colorectal cancer that hasn't responded to standard treatments. Participants must have measurable disease, be in a relatively stable physical condition (ECOG score 0-2), and have good heart, blood, liver, and kidney function. Women who can become pregnant must test negative for pregnancy and all participants should agree to use contraception.Check my eligibility

What is being tested?

The study is testing the effectiveness of Aroplatin on patients with advanced colorectal cancer resistant to other drugs. It aims to see how well patients respond to this treatment and how long they stay responsive. The safety and tolerability of Aroplatin are also key points being evaluated.See study design

What are the potential side effects?

While specific side effects aren't listed here, common ones associated with chemotherapy like Aroplatin may include nausea, vomiting, fatigue, decreased appetite, hair loss, neuropathy (nerve problems), as well as increased risk of infection due to lowered white blood cell counts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a woman who can have children and my pregnancy test is negative.

Select...

My colorectal cancer has spread and cannot be removed by surgery.

Select...

My cancer did not respond to treatments including 5-FU, leucovorin, capecitabine, or irinotecan.

Select...

I am able to care for myself and move around.

Select...

My heart works well enough for daily activities without severe symptoms.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Aronex PharmaceuticalsLead Sponsor

5 Previous Clinical Trials

268 Total Patients Enrolled

Media Library

Aroplatin (Platinum-based Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00043199 — Phase 2

Colorectal Cancer Research Study Groups:

Colorectal Cancer Clinical Trial 2023: Aroplatin Highlights & Side Effects. Trial Name: NCT00043199 — Phase 2

Aroplatin (Platinum-based Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00043199 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the Food and Drug Administration sanction this therapy?

"The safety profile of this treatment was rated a 2 on our scale, as there is evidence for its security but no data demonstrating efficacy."

Answered by AI

Does the eligibility criteria of this clinical trial encompass individuals over 35 years old?

"To qualify for this medical study, participants must be aged 18 to 65. Furthermore, there are 324 trials targeting those younger than eighteen and 2,933 research initiatives dedicated to people over sixty-five years old."

Answered by AI

Who would qualify to become a participant in this clinical research?

"This trial is searching for 40 volunteers who have been diagnosed with colorectal cancer and are aged between 18 to 65. In order to be eligible, participants must exhibit adequate hematopoietic, hepatic and renal function; present measurable signs of the disease (RECIST criteria); suffer from an illness that has not responded positively to 5-FU/leucovorin or capecitabine in combination with irinotecan; possess a ECOG performance score of 0-2; demonstrate acceptable cardiac health (maximum CLASS II according to NYHA); pass urine or serum pregnancy test if applicable; sign written informed"

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

2024. "A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00043199.

All > Colorectal Cancer > Bowel Cancer